Glatiramer acetate is a treatment option in neutralising antibodies to interferon-beta-positive patients
Tóm tắt
Neutralising antibodies develop in 15% of interferon-beta (IFNβ)-treated patients, causing the reduction of the clinical effects of the treatment. This is the first study that shows that switching patients from IFNβ to glatiramer acetate (GA) in case of neutralising antibodies (NAb) positivity is effective in reducing relapse rate and in delaying the time to first relapse. In conclusion, our data suggest the use of GA in NAb-positive patients.
Tài liệu tham khảo
Bertolotto A, Malucchi S, Sala A et al (2002) Differential effects of three interferon betas on neutralising antibodies in patients with multiple sclerosis: a follow-up study in an independent laboratory. J Neurol Neurosurg Psychiatry 73:148–153
Bellomi F, Scagnolari C, Tomassini V et al (2003) Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years. J Neurol Sci 215:3–8
Gilli F, Bertolotto A, Sala A et al (2004) Neutralizing antibodies against IFN-b in multiple sclerosis: antagonization of IFN-b mediated suppression of MMPs. Brain 127:259–268
Gilli F, Marnetto F, Caldano M et al (2006) Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler 12:1–11
Sorensen PS, Ross C, Klemmesen KM et al (2003) Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 362:1184–1191
Sorensen PS, Deisenhammer F, Duda P et al (2005) Guidelines on use of anti-IFN-b antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFNβ antibodies in multiple sclerosis. Eur J Neurol 12:817–827
Rovaris M, Comi G, Rocca MA et al (2007) Long-term follow-up of patients treated with glatiramer acetate: a multicentre, multinational extension of the European/Canadian double-blind, placebo-controlled, MRI-monitored trial. Mult Scler 13:502–508
Caon C, Din M, Ching W et al (2006) Clinical course after change of immunomodulating therapy in relapsing-remitting multiple sclerosis. Eur J Neurol 13:471–474
Carrà A, Onaha P, Luetic G et al (2008) Therapeutic outcomes 3 years after switching of immunomodulatory therapies in patients with relapsing remitting multiple sclerosis in Argentina. Eur J Neurol 15:386–393
Pozzilli C, Antonini G, Bagnato F et al (2002) Monthly corticosteroids decrease neutralizing antibodies to IFN-beta1 b: a randomized trial in multiple sclerosis. J Neurol 249:50–56